Multiple sclerosis is a chronic demyelinating disease which causes significant disability in young adults. It is an autoimmune disorder that results in inflammation and scarring of the myelin sheaths covering nerves within a human body. Multiple sclerosis is more common in women than men. Multiple sclerosis can be broadly classified into four types: RRMS, SPMS, PPMS, and PRMS. When multiple sclerosis symptoms flare up, it is known as relapsing-remitting multiple sclerosis (RRMS) which usually starts at the age of 20 or 30. Patients with severe multiple sclerosis can experience speech and movement problems.
The major symptoms of relapsing-remitting multiple sclerosis (RRMS) are eye pain, vision problems, numbness, tingling, sensitivity to heat, pain that runs down the spine, dizziness, bowel or bladder problems, sexual problems, stiff muscles, feeling weak and tired, problems with balance and coordination, unclear thinking and depression. No two people are likely to have the same symptoms and the symptoms depend on the damaged area of brain or spinal cord. The relapsing-remitting multiple sclerosis (RRMS) attacks can last anywhere from 24 hours to several weeks involving one or many symptoms or the already existing problem that gets worse with a new symptom.
According to the study “Relapsing Remitting Multiple Sclerosis (RRMS) Global Clinical Trials Review, H1, 2018”, medication, physical therapy and healthy habits are adopted by the patient to manage their relapsing-remitting multiple sclerosis (RRMS). It is necessary to treat relapsing-remitting multiple sclerosis (RRMS) immediately after diagnosed to avoid lasting nerve damage. Few medications for RRMS fight the disease by turning down the body’s immune system so that it doesn’t attack nerves. Treatment of RRMS is through disease-modifying drugs (DMDs) or immunotherapy or disease-modifying therapy (DMT).
Clinical trials are performed to develop better options to prevent, treat or diagnose RRMS. It helps making healthcare decisions easier and faster with awareness in scientific standards that protect the interests of the patients. Clinical trial is the final and most important stage within the medical sector. Clinical trials happen in four phases, they are, experimental study of drug, same study on more number of people which may extend up to years, test for safety and efficacy of drug on human race and study of side effects and finally approval from relevant authority for the usage of drug. Research on relapsing-remitting multiple sclerosis involves the most promising and naturally occurring antiviral proteins known as interferons. Beta interferon is one such protein exhibiting the reduction of number of exacerbations and may help slow the progression of physical disability. Various treatments are under the radar to minimize attacks and improve function of interferons. More than a dozen clinical trials are tested for potential therapies which are in pipeline coupled with the development of additional treatments.
The leading competitors in global relapsing-remitting multiple sclerosis (RRMS) market are Biogen Inc, Novartis AG, Sanofi, Teva Pharmaceutical Industries Ltd, Bayer AG, E. Merck KG, GlaxoSmithKline Plc, F. Hoffmann-La Roche Ltd, AbbVie Inc, and Johnson & Johnson. It was predicted that with the introduction of mesenchymal stem cells therapy is the most promising investigational approach to treat multiple sclerosis. Globally, American CryoStem, Athersys, Celgene Cellular Therapeutics and Cell Cure Neurosciences are the leading companies actively involved in the development of stem cell therapy molecules for the treatment of relapsing-remitting multiple sclerosis. Therapeutic assessment of the stem cell therapy for relapsing-remitting multiple sclerosis RRMS is through intravenous and intracerebroventricular procedures. Majority of stem cell therapies within the relapsing-remitting multiple sclerosis (RRMS) category are being developed as intravenous drugs. Therefore, clinical trials in global relapsing-remitting multiple sclerosis (RRMS) will witness a positive evolution of stem cell therapies over the next few years.
To know more, click on the link below:
https://www.kenresearch.com/healthcare/pharmaceuticals/relapsing-remitting-multiple/154894-91.html
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-9015378249
